Clincosm LogoSign in Get a demo

TNBC - Triple-Negative Breast Cancer

Showing 26 - 35 of 35
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
May 29, 2022

Solid Tumor, TNBC - Triple-Negative Breast Cancer Trial in Bengbu, Beijing (LAE005 + Afuresertib + Nab-Paclitaxel, LAE005 +

Recruiting
  • Solid Tumor
  • TNBC - Triple-Negative Breast Cancer
  • LAE005 + Afuresertib + Nab-Paclitaxel
  • +3 more
  • Bengbu, Anhui, China
  • +1 more
May 19, 2022

Triple Negative Breast Cancer, Triple Negative Breast Tumors, TNBC - Triple-Negative Breast Cancer Trial in Saint Louis (drug,

Active, not recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 14, 2022

Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer Trial in United States (CB-839, Talazoparib)

Terminated
Has Results
  • Solid Tumor
  • +6 more
  • Birmingham, Alabama
  • +8 more
Feb 16, 2022

TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (olaparib, Durvalumab)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • +2 more
  • (no location specified)
Jan 12, 2022

TNBC - Triple-Negative Breast Cancer Trial in United States (Gedatolisib, Talazoparib)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Chicago, Illinois
  • +4 more
Jan 18, 2022

Cancer, Tumor, Solid, Malignant Tumor Trial in Scottsdale, Austin, San Antonio (OR2805, Pembrolizumab, Nivolumab)

Recruiting
  • Cancer
  • +8 more
  • Scottsdale, Arizona
  • +2 more
Oct 15, 2021

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial in United States (Pembrolizumab,

Recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Sep 15, 2021

TNBC - Triple-Negative Breast Cancer Trial in Seoul (Talazoparib, Placebo)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Feb 14, 2021

TNBC - Triple-Negative Breast Cancer Trial in Shanghai (A1: Pyrotinib with Capecitabine, A2: nab-paclitaxel, B1: everolimus with

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • A1: Pyrotinib with Capecitabine
  • +9 more
  • Shanghai, Shanghai, China
    Cancer Hospital Affiliated to Fudan University
May 19, 2020